**Group A**
- Tumor ≤ 3 mm in height
- Tumor ≥ 2 DD (3mm) from fovea AND ≥ 1 DD (1.5mm) from optic nerve
- NO vitreous seeding
- NO retinal detachment

**Group B**
- Tumor > 3 mm in height
- Retinal detachment ≤ 5 mm from edge of tumor OR no retinal detachment
- NO vitreous seeding

**Group C**
- Local, fine limited seeds (i.e. treatable by plaque)
- AND/OR
- Retinal detachment up to 1 quadrant

**Group D**
- Diffuse vitreous and or subretinal seeding and or
- Massive non discrete endo e ophytic disease
- E ophytic disease and retinal detachment 1 quadrant up to total retinal detachment

**Group E**
Presence of any one or more of :
- Irreversible neovascular glaucoma
- Massive intraocular haemorrhage
- Anterior to anterior vitreous face
- Aseptic orbital cellulitis
- Tumour touching the lens
- Diffuse infiltrating retinoblastoma
- Phthisis or prephthisis
<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>0</strong></td>
<td>Patient treated conservatively</td>
</tr>
<tr>
<td><strong>I</strong></td>
<td>Eye enucleated: complete histological resection</td>
</tr>
</tbody>
</table>
| **II** | Eye enucleated: microscopic residual tumour risk i.e invasion of:  
  - optic nerve  
  - choroid (massive >3mm)  
  - anterior chamber  
  - sclera  
| **III**| Regional extension  
  a. Overt orbital disease  
  b. Preauricular or cervical node extension |
| **IV** | Metastatic disease  
  a. Haematogenous metastasis, no CNS  
    1. Single  
    . Multiple  
  b. CNS extension  
    1. Prechiasmatic  
    . CNS mass  
    . Leptomeningeal disease |
Chemotherapy for Retinoblastoma

Dr Helen Jenkinson
Consultant Paediatric Oncologist, Birmingham Children’s Hospital
Helen.jenkinson@bch.nhs.uk

Indications for chemotherapy in the management of intra-ocular retinoblastoma

Unilateral retinoblastoma

a) Neoadjuvant chemoreduction prior to local therapy. Chemotherapy may be used in localised tumours grade B or C in which there is a reasonable prospect of salvage of the globe and/or visual or in more advanced tumours in an eye thought to have potential for useful vision. In certain situations, such as tumours involving the macula, it may be possible to avoid the use of local therapy in order to preserve vision although most cases will require some local therapy once the tumour has shown maximal shrinkage.

b) Post-primary enucleation for adverse histological features including:
   - retrolaminar invasion of optic nerve
   - disease in the anterior chamber
   - deep choroidal invasion:

Management of unilateral RB following primary enucleation:

Unilateral RB enucleation

Histology review

No adverse histological features

No further treatment
Observe

Adverse histological features
See above

4 cycles of JOE chemotherapy
Bilateral retinoblastoma
Management of bilateral tumours must be tailored to the individual case. The aim of treatment is to attempt to retain useful vision in at least one eye. In cases of advanced bilateral tumours this may involve enucleating the eye containing the most advanced tumour and using chemotherapy to reduce the tumour in the remaining eye rendering it amenable to local therapy. Chemotherapy may also reduce tumours bilaterally facilitating local therapy and thus avoiding the need for enucleation.

Metastatic retinoblastoma
The vast majority of patients present with intraocular retinoblastoma for which the 5-year survival is in excess of 95%. However, retinoblastoma may metastasize either locally or to distant sites (bone, CNS, liver), a situation more commonly seen in the developing world when access to health care results in later disease presentation. Metastatic RB has a very poor prognosis with conventional therapy and is highly lethal. Recent use of aggressive multi-modality therapy including conventional chemotherapy, high-dose chemotherapy with autologous stem cell rescue and radiation has improved the outlook and improved the prospect of cure in a limited number of patients.
Chemotherapy Protocols

The first-line chemotherapy agents used in the management of retinoblastoma are vincristine, carboplatin and etoposide and all or a combination of these agents, are generally used around the world as first line agents.

**UK Protocol for first line chemotherapy (JOE)**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Vincristine day 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dosage</td>
<td>1.5 mg m² or children 10 kg</td>
</tr>
<tr>
<td>Administration</td>
<td>Intravenous bolus ma total dose 2 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug</th>
<th>Carboplatin day 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dosage</td>
<td>600 mg m² or children 10 kg</td>
</tr>
<tr>
<td>Administration</td>
<td>Infuse over 1 hour</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug</th>
<th>Etoposide</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dosage</td>
<td>300 mg m² or children 10 kg</td>
</tr>
<tr>
<td>Administration</td>
<td>Infuse over 4 hours</td>
</tr>
</tbody>
</table>

Each course given at approximately 21 day intervals, when the neutrophils are >1x10⁹/l and platelets >100x10⁹/l.

**Recommendations for children under 10kg in weight:**
- Less than 6 months of age: 50% of calculated dose by body surface area
- 6 months to 1 year of age: 75% of calculated dose by body surface area
- Over 1 year of age: 100% of calculated dose by body surface area

Indications or second-line chemotherapy include:

a. Recurrent intra-ocular RB following first line chemotherapy.

There are a number of therapeutic options or children who have an intraocular relapse after prior treatment with standard first line chemotherapy. These include cryotherapy, laser - carboplatin monotherapy, chemothermotherapy, scleral plaque radiotherapy, second line chemotherapy or external beam radiotherapy. Children with vitreous disease or relapsed tumours not suitable for focal therapy and whom radiotherapy is the last option, should be considered for second line chemotherapy.

The presence of vitreous disease is also an indication for sub-conjunctival carboplatin.
b) Second line chemotherapy is also indicated as adjuvant therapy following enucleation of an eye which has failed standard first line chemotherapy (Vincristine, Etoposide and Carboplatin).

**UK Protocol for Second line Chemotherapy (IVAd)**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage</th>
<th>Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vincristine</td>
<td>1.5 mg m$^2$ or children 10 kg</td>
<td>Intravenous bolus ma total dose 2 mg</td>
</tr>
<tr>
<td>Doxorubicin (Adriamycin)</td>
<td>25 mg m$^2$ dose or children 10 kg</td>
<td>Infuse over 4 hours</td>
</tr>
<tr>
<td>Ifosfamide Days 1 + 2</td>
<td>os amide 3 gm m$^2$ dose or children 10 kg</td>
<td>Infuse over 3 hours</td>
</tr>
</tbody>
</table>

Recommendations for children under 10 kg in weight See above

There are very few children requiring chemotherapy for progressive or recurrent disease following both first and second-line therapy. These children must be managed on an individual basis and the risks associated with further chemotherapy evaluated against the likely benefit.

**Late Effects of Therapy for Retinoblastoma**

Survivors of RB face long term consequences associated with both the cancer and its treatment. These include:

a) Chemotherapy-related late effects

The risks of chemotherapy associated late effects are directly related to the treatment received and most agents have known toxic effects which many not become manifest until later in life. Each of the agents used in retinoblastoma requires specific long-term surveillance.
The potential late adverse effects of chemotherapy for RB are:

- **Carboplatin** – auditory and renal dysfunction
- **Etoposide** – secondary leukaemia
- **Vincristine** – peripheral neuropathy
- **Ifosfamide** – secondary leukaemia, gonadal dysfunction and renal/bladder dysfunction
- **Doxorubicin** – cardiac dysfunction

Standard UK protocols for the management of late chemotherapy toxicity are available online at [www.cclg.org.uk](http://www.cclg.org.uk)

**b) Radiotherapy related late effects**

In view of the significant late effects associated with external beam radiotherapy, it now tends to be reserved for salvage treatment of RB if frontline therapies have failed. The side effects include:

- Eye related problems dependent on technique: cataract formation, retinal changes, lacrimal gland dysfunction
- Bone and soft tissue hypoplasia
- Pituitary dysfunction
- Second malignant neoplasms within and on the edge of the radiation field

**c) Psychosocial and visual late effects**

Many children treated for RB will have long term visual impairment which may range from monocular vision secondary to unilateral enucleation to blindness. Some children are registered partially sighted or blind and many require additional support in mainstream school or specialised schooling. The impact of this on the child’s psychosocial development including educational performance, mobility, independence, social functioning, peer acceptance and self-esteem must be considered. Long term follow-up or survivors of RB should include multidisciplinary access to specialised nurses, psychology, play therapy and social work.
d Second Malignancies

In the heritable type of retinoblastoma there is a high risk that a second, non-ocular, cancer will develop later in life. This increased risk is associated with the radiation used in treating retinoblastoma and the presence of the RB1 gene mutation which increases the risk of subsequent cancers. In the non-heritable type there will also be a, much smaller, increased risk for patients exposed to radiation to treat their retinoblastoma.

On the basis of research studies in Great Britain and the Netherlands we calculate that of every 100 people surviving heritable retinoblastoma:

- 3 will develop cancer by age 10
- 8 “ “ “ “ 20
- 11 “ “ “ “ 30
- 20 “ “ “ “ 40
- 30 “ “ “ “ 50

Thus, there is a high risk of a second cancer among people with heritable retinoblastoma. However, of every 100 people in Great Britain about 35 will eventually develop a cancer.

The types of second cancer seen in RB are: osteosarcomas, rhabdomyosarcoma, fibrosarcoma, leiomyosarcoma, brain tumours, melanoma and some epithelial tumours such as lung and bladder cancer.

The CCLG Retinoblastoma working group in the UK have developed guidelines for the long term follow-up of RB patients. The frequency, duration and nature of long-term follow-up of patients treated for retinoblastoma is dependent upon whether:

- RB is hereditary or non-hereditary
- Cytotoxic treatment was received or the retinoblastoma, particularly exposure to radiotherapy or chemotherapy
- Radiotherapy was received
- Extent of visual impairment

These will be available soon on the Children’s Cancer and Leukaemia Group (CCLG) website www.cclg.org.uk
Intra-ophthalmic arterial chemotherapy for the treatment of Retinoblastoma

Background

Intra-arterial chemotherapy has the potential benefit of delivering chemotherapy locally, in high concentrations to enhance the therapeutic effect while minimising systemic toxicity. Since 1993 semi-selective intra-arterial chemotherapy has been used routinely in Japan and a similar technique but using direct intra-ophthalmic artery catheterisation with modern micro-catheters has been used by the team in New York since 2006. It has growing acceptance within the international retinoblastoma community and reports indicate that ocular event-free survival at 2 years event being enucleation or BR is 67 or all eyes, 75 or eyes undergoing AC as primary treatment and 63 or eyes that had ailed previously with systemic chemotherapy or BR.

Indications:

Bilateral Retinoblastoma

1. In a child who has had one eye enucleated and the remaining eye has potential or vision but has ailed 1st line therapy - prior salvage therapy chemotherapy having been included in either the 1st line or salvage therapy and where A Melphalan is considered the best therapeutic option.

2. In a child with both eyes in situ, where the eye to be treated has a reasonable prospect or vision having ailed 1st line therapy - prior salvage therapy chemotherapy having been included in either the 1st line or salvage therapy and where A Melphalan is considered the best therapeutic option.

Unilateral Retinoblastoma

1. A chemotherapy may be considered in situations where a unilaterally a ected eye with potential or vision, has ailed irst line conservative therapy which has included chemotherapy, but still has potential or vision and where A Melphalan is considered the best therapeutic option.
The potential risks associated with IA chemotherapy include:

- Risks of a general anaesthetic
- Bleeding from the arterial puncture, haematoma or arterial thrombus resulting in compromised circulation to the lower limb.
- There is a very small risk that the procedure may compromise cerebral circulation resulting in cerebrovascular accident.
- Mild myelosuppression following intra-arterial chemotherapy
- Children may experience swelling around the eye, flushing of the skin around the eye and forehead, transient 3rd nerve palsy and droopiness of the eyelid.
- A number of children experience a drop in the vision in the treated eye which may be temporary or in a small number of cases permanent. Occasionally total loss of vision in the affected has been reported.

There have been reports of children experiencing hypotension and bradycardia during the procedure prior to the infusion of the melphalan. This seems to be related to mechanical instrumentation of the internal carotid artery and responds to adrenaline promptly.
Overview of clinical and molecular genetic management in Retinoblastoma

Dr Trevor Cole, Consultant in Clinical and Cancer Genetics
West Midlands Regional Genetics Service
Birmingham Women’s NHS Foundation Trust, Birmingham B15 2TG, UK.
e-mail Trevor.Cole@bwhct.nhs.uk

Introduction

Retinoblastoma, although rare acting 1 in 20,000 children, is often cited as a paradigm for our understanding and management of cancer genetic disorders.

It has long been recognised as a dominantly inherited disorder when present in the familial form. However, most cases are not apparently inherited (>90%) and of these are unilateral and non-inherited in at least 60% of cases or bilateral and de novo in the remainder (1,2).

Familial and bilateral cases are almost invariably due to an inherited mutation and have an earlier age of diagnosis to unilateral cases (mean age 8 months compared to 25 months). Examination of this epidemiological data led Knudson to postulate the two hit hypothesis of tumour development (3). This was subsequently confirmed when the retinoblastoma gene was cloned by Friend et al in 1986 (4).

Subsequent molecular analysis of germline and tumour DNA in unilateral cases confirmed that approximately 15% of these cases are inherited and that the remainder have usually have two identifiable mutations confined to the tumour and absent in the blood. Hence these are likely to be somatic mutations not present in the affected individual's germline with a low risk of vertical transmission.

This knowledge and data is compatible with the empirical data on recurrence risk in families if due consideration is given to the fact that a small proportion of cases will exhibit mosaicism in the tissues of affected children or in the gonadal tissue of parents.

The significance of mosaicism will be illustrated and its management implications discussed. We also will discuss whether novel or improvement in molecular techniques such as allelic specific amplification or next generation sequencing should modify our current screening protocols (6,7) or if DNA may influence our prenatal and perinatal management.
10 Points on the Genetic Management of Retinoblastoma Cases

After the identification of any child with retinoblastoma the following processes need to be considered see appendix 1:

1. Is there a family history indicating autosomal dominant inheritance? Be careful to consider non-penetrance in unilateral cases.

2. A unilateral case is very early onset (<12 months) or multifocal might this case subsequently present as a bilateral case and hence be a heritable form of Rb.

3. Consider appropriate genetic testing. Chromosomes are certainly indicated if there is evidence of developmental delay, dysmorphic features or a history of miscarriage. Chromosome analysis will not detect more subtle molecular changes and there is debate on whether they are indicated in the absence of the three features above. For inherited or bilateral cases molecular analysis of the germline is always indicated. For unilateral cases post enucleation start with somatic tumour studies. If no tumour tissue is available then it is used to request germline studies.

4. If the results of paragraph 3 above are negative consider role of linkage testing in the family. This may allow exclusion of individuals from surveillance programmes.

5. For families with informative molecular results work back through each relevant branch of the family until their risk is excluded and they are identified as at population risk.

6. Consider the possibility of mosaicism in unilateral cases and unaffected parents of bilateral cases. This is important so not to miss offspring risk from gonadal mosaicism.

7. Molecular tests should be instigated in all cases, where possible, as informative results will potentially identify all individuals at risk of developing or transmitting Rb. Informative results will also typically exclude a larger number of individuals who do not need screening.

Failure to pursue genetic testing, whether by the family or doctor, has significant implications:

a. at risk patients may be overlooked, a particular risk in low penetrant families.
b. many patients may receive unnecessary surveillance, at avoidable cost to the family or healthcare system. This usually is greater than the cost of molecular testing.
c. unnecessary surveillance is associated with avoidable morbidity, and even a small risk of anaesthetic mortality.

There are no molecular analysis should be seen as cost effective and standard best practice and not a selectable “add on”.

Only if molecular investigation is uninformative, <10% of bilateral disease or unilateral enucleations, should empirical data be used or definite counselling of families and instigating surveillance. Empirical data is attached appendix 2 – modified from Musarella and Gallie 1 7 10 and A practical guide to human cancer genetics 2.
As the detection rate of molecular testing increases ever nearer to 100% with techniques such as allelic specific PCR or next generation sequencing, the residual risk of “non informative cases” due to mosaicism decreases. Therefore, there needs to be an iterative evidence based and informed debate of the protocols for screening.

Updated 21/2/2011

References

1 Website www.geneclinics.org


7 Anna Rohlin, Josephine Wernersson, vonne ngwall, ei Wiklund, an B rk, Margareta Nordling. Parallel sequencing used in detection of mosaic mutations: comparison with our diagnostic DNA screening techniques. Human Mutation 30 1012-1020 200


Appendix 1

Algorithm for the Clinical and Molecular Genetic Management of Retinoblastoma
Appendix 2

Empiric risk data for relatives of isolated case of retinoblastoma

Modified from Musarella and Gallie 1987 and A Practical Guide to Human Cancer Genetics Ed Hodgson, Foulkes and Maher

<table>
<thead>
<tr>
<th>Nature of Retinoblastoma in proband</th>
<th>Relationship to Proband</th>
<th>Likelihood of being a gene carrier</th>
<th>Likelihood of developing a retinoblastoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bilateral</td>
<td>M Twin</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>Bilateral</td>
<td>Offspring</td>
<td>50</td>
<td>45</td>
</tr>
<tr>
<td>Bilateral</td>
<td>Sibling</td>
<td>5</td>
<td>2.7</td>
</tr>
<tr>
<td>Bilateral</td>
<td>Offspring unaffected sibling</td>
<td>0.5</td>
<td>0.27</td>
</tr>
<tr>
<td>Bilateral</td>
<td>First cousin</td>
<td>0.05</td>
<td>0.027</td>
</tr>
<tr>
<td>Unilateral</td>
<td>M Twin</td>
<td>10</td>
<td>5.4</td>
</tr>
<tr>
<td>Unilateral</td>
<td>Offspring</td>
<td>7.5</td>
<td>5.7</td>
</tr>
<tr>
<td>Unilateral</td>
<td>Sibling</td>
<td>0.0</td>
<td>0.4</td>
</tr>
<tr>
<td>Unilateral</td>
<td>Offspring unaffected sibling</td>
<td>0.0</td>
<td>0.04</td>
</tr>
<tr>
<td>Unilateral</td>
<td>First cousin</td>
<td>0.00</td>
<td>0.004</td>
</tr>
</tbody>
</table>

The risk of developing a retinoblastoma was calculated assuming a 90% penetrance in gene carriers which is probably an underestimate.

Any full sibling other than MZ twin. Risk of half sibling would be expected to be half this figure.
Appendix 3

PROTOCOL FOR SCREENING SIBLING AND OFFSPRING OF PATIENTS WITH RETINOBLASTOMA

Dilated fundus examination
- within a week of delivery
- Monthly to 6 months of age
- 2 monthly to 2 years of age
- 3 monthly to 3 years of age
- 4 monthly to 4 years of age
- 6 monthly to 7 years of age

Screening to be discontinued only if genetic testing results show a patient does not carry the RB mutation.

Where Rb mutation is not proven in parent, patient should be advised to seek genetic counselling at age 16.

Proband genetic testing should be repeated if not up to date.

A sibling is a proven gene carrier but no tumour identified their surveillance would continue 6 monthly to age 10 as affected retinoblastoma cases
Definitions of Some Relevant Genetic Terms

**Molecular and Genetic Terms and Definitions**

**Sequencing** – method or reading individual base pairs within a gene. Considered the gold-standard or mutation detection. Will usually sometimes not detect whole gene deletions, whole on deletions or mutations within introns.

**SSCP (single strand conformational polymorphisms) and heteroduplex analysis** – these are methods of scanning genes or “small mutations”. These mutations are detected by changes in the rate of migration of the altered gene sequence through gels. The detection rates are variable but less than sequencing.

**MLPA – multiplex ligation–dependent probe amplification** – this method is useful or the detection of large intragenic deletions and duplications.

**Linkage analysis** – method of tracking markers through family members to try and identify regions of genetic material co-segregating with a disease or phenotype. This does not identify a mutation but can identify or exclude gene carriers indirectly. The analysis requires DNA and knowledge of the phenotype from more than one person in a family.

**Recombination** – rearrangement of genetic material between homologous chromosomes so that two linked markers or a phenotype and a marker are no longer co-segregating on the same chromosome. The closer the markers are situated, the less likely a recombination event is to occur. Recombination results in an error rate which should be quoted or linkage studies.

**Chromosome analysis or karyotype analysis** – this is a separate genetic test from mutation studies. The analysis will only detect large chromosomal deletions, duplications or rearrangements and not mutations within a gene.

**Segregation analysis** – analysis of the inheritance of phenotype or genotype to see if it is manifesting in a mendelian fashion, if this is dominant or recessive and also if autosomal or linked.

**Free fetal DNA (ffDNA)** – DNA from a fetus is leaked in small amount into the maternal circulation. This is usually detectable in increasing amounts about 7 weeks but has a half-life of 6 hours so is rapidly cleared after delivery. The paternal contribution of this DNA is different from mothers and therefore paternally inherited mutations should be detectable in mothers blood.

**Mutation Types**

**Missense mutation** – change of the amino acid sequence but a full length protein is still usually produced. It can be difficult to determine if a missense mutation is truly...
pathogenic. Supporting evidence of pathogenicity includes showing such changes are de novo in an isolated case, or is co-segregating with the phenotype in a family or has previously been reported in other families. Functional studies may help determine significance in some cases.

**Nonsense mutation** – sequence change which introduces a stop codon into a gene and results in a truncated protein, these are usually pathogenic.

**Frameshift mutation** - sequence change which affects 1 or more base pairs but not a multiple of three so the reading frame of the gene organised in codons of three base pairs is disrupted. These mutations will alter amino acids after the frameshift mutation and result in an abnormal stop codon. They are usually pathogenic.

**Splice site mutation** – a gene sequence change in the region of the exon (coding) / intron (non-coding) boundary. The DNA is usually processed so the introns are spliced out and the exons joined. Failure to recognise the boundary can lead to exons being erroneously spliced out. These changes can be difficult to detect if the mutations are in intronic regions. It can also be difficult to determine if they are pathological and some of the same mechanisms described under missense mutations may be used.

**RNA analysis** – analysis of RNA rather than DNA, the former of which is technically more difficult and has only limited availability in non-research settings. Can be useful to investigate splice site mutations and exon skipping.

**Other Genetic Terms**

**Penetrance** – the frequency a phenotype is manifest with a particular genotype

**Expressivity** – the variable nature or severity of a phenotype with a specific genotype.

**Mosaicism** – the presence of a mutation in some cells but not all cells in a multicellular organism. This is important to understand as an Rb mutation could be present in both retina but not necessarily detectable in the blood. Such a mutation could, theoretically, also be present in the gonads although not the blood.

**Gonadal mosaicism** – presence of a mutation in some or all of the gonadal cells but not all cells within a multi-cellular organism. It is important to be aware of the possibility as a mutation not detected in the blood may still be present in the gonads and thus transmitted to the next generation.
Protocol for retinoblastoma screening

A. Bilateral proband: only member of family affected

B Unilateral proband: only member of family affected
When the RB1 mutation(s) are not known, the % risk for the relatives of retinoblastoma patients to develop retinoblastoma can be estimated to be high (red) or moderate (turquoise).

Modified from Figure 11. A. Valenzuela, H. S. L. Chan, E. Héon, B. L. Gallie A Language for Retinoblastoma: Guidelines Through Standard Operating Procedures Pediatric Retina. Reynolds J, Editor. Kind permission from Prof Brenda Gallie, Hospital for Sick Children, Toronto.

Key

<table>
<thead>
<tr>
<th>Color</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Black</td>
<td>Patient with retinoblastoma</td>
</tr>
<tr>
<td>Red</td>
<td>Relative of retinoblastoma patient with high risk of developing retinoblastoma</td>
</tr>
<tr>
<td>Turquoise</td>
<td>Relative of retinoblastoma patient with moderate risk of developing retinoblastoma</td>
</tr>
</tbody>
</table>
Protocols for Retinoblastoma

Dr Manoj Parulekar
Consultant Paediatric Ophthalmologist, Birmingham Children's Hospital
manoj.parulekar@bch.nhs.uk

Follow up Protocol or patients

**During treatment**

Chemotherapy is typically given over 6 cycles at 3-4 weekly intervals

**During Chemotherapy local laser cryo therapy**

very 3-4 weeks or most cases. The timing of UA and treatment is coordinated to precede the next cycle of chemotherapy. This allows the maximum effect of each chemo cycle to occur so that focal treatment can be more effectively performed, and also allows time for the blood counts to recover, making GA and local treatment safer.

Review every 2-3 weeks

- if no chemotherapy is used - i.e. cases with very small tumours that can be managed with focal treatment alone.
- for very large tumours where it may not be possible to treat the entire tumour at each sitting
- or rapidly growing macular tumours.

Following enucleation –
All cases receive a 1-2 week socket check in clinic.
Following this-
Unilateral - 6 week UA allowed by artificial eye fitting
Bilateral - Receive 3-4 weekly UAs or the other eye. Artificial eye fitting 6 weeks post op.

**Following successful treatment**

UA or Clinic depending on co-operation

**Unilateral** – every 2 months or 6 months
  - every 3 months or 12 months
  - every 4 months or 12 months
  - every 6 months to age 10

Aim to transfer care to local ophthalmologist after 12 months disease free.
Bilateral - every 2 months or 12 months
               every 3 months or 12 months
               every 4 months or 12 months
               every 6 months to age 16
Aim or local follow up after 24 months disease free

The transition from EUAs is often gradual, initially alternating between UA and clinic or a few visits before switching to clinic only.

Screening of the immediate family

All siblings and both parents should have undus examination at the time of proband diagnosis

Offspring and siblings of parents with retinoblastoma

See genetics handout

References
PRESENTATION AND DIFFERENTIAL DIAGNOSIS

Dr Manoj Parulekar
Paediatric Ophthalmologist, Birmingham Children’s Hospital, UK
manojparulekar@aol.com

INCIDENCE

1:23,000 live births - 40 – 45 new cases per year UK
- 1 0 – 200 new cases per year USA
Represents 3 o childhood cancers

35% - 40% Bilateral
- 15 ve amily history
- 5 New germline mutation
- Mean age presentation is 13 months

60% - 65% Unilateral
- 15 have germline mutation
- Mean age presentation is 24 months

PRESENTATION

Leukocoria (yellow/white pupillary re le 60 - 65
Strabismus 30 - 35

Acute in lammation
Pseudohypopyon tumour tissue in the anterior chamber
Rubeosis giving rise to ac uired heterochromia
Buphthalmos traocular spread
Raised intracranial pressure

DIFFERENTIAL DIAGNOSIS OF LEUKOCORIA

Artefact (commonest)
O a is lash photographs

1. Batra R, Rowe F, Rowlands A, Noonan C. Unilateral leucocoria in clinically
2. i , Coats DK, Fung D, Smith O, Paysse . The detection o simulated retinoblastoma by using
3. American Academy o Pediatrics Section on Ophthalmology American Association or Pediatric
Ophthalmology And Strabismus American Association o Ophthalmology And Strabismus American Association o
Anterior Segment disease

Cataract  
Corneal opacity  
Hypopyon

Posterior Segment disease

Coat’s disease

Coats disease, an exudative retinal vasculopathy is the commonest other diagnosis in cases with suspected retinoblastoma. Important differentiating features between the two include:

<table>
<thead>
<tr>
<th>Feature</th>
<th>Coat’s</th>
<th>RB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retinal reflex</td>
<td>Yellow reflex (xanthocoria)</td>
<td>White reflex (leucocoria)</td>
</tr>
<tr>
<td>Vitreous</td>
<td>Clear</td>
<td>May have seeds</td>
</tr>
<tr>
<td>Examination and USG B scan</td>
<td>Absent</td>
<td>Present</td>
</tr>
<tr>
<td>Large dilated tortuous vessels</td>
<td>Often present in periphery in one or more quadrants</td>
<td>Vessels may be dilated but less likely to be tortuous, and usually not localised to a quadrant</td>
</tr>
<tr>
<td>Retinal detachment</td>
<td>Usually total detachment with subretinal exudation</td>
<td>Retina may may not be detached, there may be multiple tumours, and scattered subretinal seeds</td>
</tr>
</tbody>
</table>

Persistent foetal vasculature - PFV or PHPV - often associated with dragged ciliary processes visible through the dilated pupil, and slight microphthalmos.

Retinal dysplasia - Norries disease

Coloboma  
Retinopathy of prematurity  
Ncontinentia Pigmenti  
Myelinated nerve fibres  
Retinal detachment Retinal folds  
Retinoschisis  
Organising vitreous haemorrhage  
Melanoma  
Epiretinal membrane

Infection / Inflammation

Toxocariasis

To oplasmosis
Intermediate Uveitis
Tuberculous Sarcoid granuloma

Neoplasia

*Isolated Retinal / optic nerve hamartoma*
*Syndromal retinal hamartoma*
*Metastatic malignancy*

Medulloepithelioma

Other

*Juvenile xanthogranuloma*
*Morning glory syndrome*

**INVESTIGATIONS**

**Old photographs**
It is helpful if the parents can bring old photographs that might demonstrate a white reflex or squint at the first visit.

**Imaging**
CT scan is best avoided due to the radiation dose which may potentiate the development of second cancers in germline cases. Ultrasound B scan might be helpful in making the diagnosis by demonstrating mass lesions with calcium in the posterior segment lesions. MRI is safer than CT scan, and indicated if the child has papilloedema or symptoms or raised intra-cranial pressure to rule out pineal lesions and/or intracranial tension.

**Blood tests**
For genetic testing
For routine haematology Full blood count etc
For routine blood chemistry Serum Creatinine, electrolytes etc